Microtubules, which are polymeric filaments composed of α-tubulin and β-tubulin heterodimers, have crucial roles in cell division and growth 1 . For example, they are a core component of the mitotic spindle that separates chromosomes during eukaryotic cell division 1 . Several families of compounds that disrupt the complex polymerization dynamics of microtubules involved in mitosis have potent anticancer activity, and microtubule-targeted agents such as the taxanes and the vinca alkaloids are important treatments for a range of cancers 1 . For example, the taxanes docetaxel and paclitaxel are among the most effective chemotherapies for metastatic breast cancer (MBC) and are widely used as first-line treatment.
With the aim of identifying drugs that might overcome some of the limitations 
Basis of discovery
Halichondrin B, a large polyether macrolide, was isolated 25 years ago from the marine sponge Halichondria okadai 2, 3 . Initial investigations found that it had potent anticancer activity and indicated that it had a microtubule-targeted antimitotic mechanism of action 2, 3 . These studies also suggested that its interactions with tubulin differed from those of other classes of microtubule-targeted drugs such as taxanes, vinca alkaloids and epothilones, which stimulated interest in the possibility that halichondrin B had unique and potentially improved anticancer activities compared with these classes 2, 3 . However, the very limited availability of halichondrin B derived from natural sources represented a major barrier to its development. The establishment of a synthetic route for its production allowed the investigation of structurally simplified synthetic analogues that retained the anticancer activity of the parent compound [2] [3] [4] . These analogues included eribulin (originally known as E7389; FIG. 1 ), which could be produced in sufficient quantities for clinical investigation.
Drug properties
Eribulin interferes with microtubule dynamics by inhibiting the growth of microtubules (with little or no effect on shortening) and by sequestering tubulin into nonproductive aggregates 3, [5] [6] [7] [8] . This leads to G2/M cell cycle arrest, disruption of mitotic spindles and apoptotic cell death after prolonged mitotic blockage 3, [5] [6] [7] [8] . Eribulin showed promising anticancer activity in various preclinical studies, including in paclitaxel-resistant cell lines, and in initial clinical studies in patients with MBC who had previously received an anthracycline and a taxane 2, 3, 8, 9 .
Clinical data
The safety and efficacy of eribulin mesylate was investigated in an open-label, randomized trial involving 762 patients with MBC who had received at least two chemotherapeutic regimens for the treatment of metastatic disease and experienced disease progression within 6 months of their last regimen 8, 10 . Patients were required to have previously received anthracycline-and taxane-based chemotherapy for adjuvant or metastatic disease, and had received a median of four prior chemotherapy regimens 8 .
Patients were randomized in a 2:1 ratio to receive eribulin mesylate administered intravenously at a dose of 1.4 mg per m 2 on days 1 and 8 of a 21-day cycle (n = 508), or a single agent therapy selected before randomization (n = 254; control group) 8 . Eribulin-treated patients received a median of five cycles of therapy 8 . The control group received therapy consisting of 97% chemotherapy (26% vinorelbine, 18% gemcitabine, 18% capecitabine, 16% taxane, 9% anthracycline and 10% other chemotherapy) and 3% hormonal therapy 8 . The primary efficacy end point was overall survival 8 . The median overall survival time for patients in the eribulin group was 13.1 months compared with 10.6 months for patients in the control group 8 . The objective response rate assessed by the RECIST criteria was 11% for patients in the eribulin group and the median response duration was 4.2 months 8 .
Indications
Eribulin mesylate is approved by the FDA for the treatment of patients with MBC who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease 8 . Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting 8 . ▶ chemotherapeutic agents currently approved for the treatment of invasive disease may show initial efficacy, the development of resistance and concerns over tolerability are common and they generally limit treatment options.
A non-taxane inhibitor of microtubule dynamics, eribulin, which was recently approved by the FDA, has shown potential to overcome acquired drug resistance in MBC. The pivotal Phase III trial, which involved a heavily pretreated MBC patient population, was designed to compare overall survival with eribulin to that with a novel comparator: treatment of physician's choice (TPC) 8, 10 . Those randomized to the TPC group received therapies that reflect the 'real life' options available to most patients with MBC at the time of the study. TPC included any single-agent chemotherapy, hormonal or biologic therapy approved for the treatment of cancer and administered according to local practice, radiotherapy, or symptomatic treatment alone. In practice, 97% of the patients in the TPC group received chemotherapy (most commonly, vinorelbine, gemcitabine or capecitabine), whereas 3% received hormonal therapy.
The trial demonstrated a statistically significant improvement in its primary end point of overall survival -by a median of 2.5 months with eribulin compared to TPC -and a manageable tolerability profile. A significant difference was also observed in overall response rate for patients with eribulin (12.2%) compared to TPC (4.7%).
Eribulin therefore represents a new option for patients with heavily pretreated MBC and is the only agent to date that has been shown to prolong overall survival of patients with heavily pretreated MBC when administered as monotherapy. Going forward, it is likely that it will be combined with other chemotherapeutics, with drugs targeting the human epidermal growth factor receptor 2 (HER2; also known as ERBB2) or with other molecularly targeted agents. Clinical trials are also underway to assess the activity of eribulin in the preoperative setting and earlier in the course of metastatic disease. 
